What is CJC-1295 + Ipamorelin?

CJC-1295 + Ipamorelin is a combination of two named research peptides in one catalogue vial. ^[4] CJC-1295 is a synthetic growth hormone-releasing hormone (GHRH) analogue, while ipamorelin is a synthetic pentapeptide growth hormone secretagogue and ghrelin-receptor agonist. ^[1][2] Peptides Collective lists the combination as 10mg from A$108 in its peptide stacks collection. ^[4]

The identifiers below describe the reference compounds, with CJC-1295 specifically referring to the verified with-DAC record. ^[1][2]

The Peptides Collective catalogue specifies the combined vial strength, but does not state how much of each component it contains or identify its CJC-1295 form as with DAC or without DAC. ^[4] Request those details alongside the batch certificate before matching the product to a particular paper.

The CJC-1295 DAC distinction matters because PubChem CID 91971820 describes an albumin-binding molecule, while products called “CJC-1295 without DAC” refer to a different, shorter molecule. ^[1] DAC means drug affinity complex; the verified structure includes a C-terminal lysine bearing a maleimidopropionyl group. ^[1]

The human CJC-1295 trials summarised in the adverse-event evidence used the DAC form. ^[5] Their findings cannot establish results for an unidentified no-DAC product or for the combined vial. ^[1][5]

There is also a naming discrepancy worth keeping visible: PubChem records CAS 446262-90-4, whereas the June 2026 Poisons Standard's CJC-1295 entry cites CAS 863288-34-0. ^[1][12] Keep the chemical reference and the legal entry attached to their respective sources. A product name alone leaves the formulation question unresolved. ^[4]

The selected CJC-1295 and Ipamorelin literature includes animal studies and human studies of the separate components. ^{[5][6][7][8][9][10][11]} It does not include a study of the combined Peptides Collective vial. ^[4][5][11] The studies answer different questions, so read the compound, model and population together.

The ipamorelin research summary also identifies cell work, including rat pituitary cells, alongside swine and rat studies. ^[8] However, no separately cell-labelled study or review appears among these selected papers. ^{[5][6][7][8][9][10][11]} Those are limits of this selection; such literature may exist elsewhere.

The human papers also differ in purpose: hormone secretion, the relationship between exposure and response, and a postoperative gastrointestinal question. ^{[5][6][10][11]} None of those subjects supplies evidence about the identity or composition of a commercial batch. ^{[5][6][10][11]} Use the paper to understand the experiment and the requested certificate to inspect the batch.

The CJC-1295 trials in healthy adults reported no serious adverse reactions, according to the abstract for PMID 16352683. ^[5] The participants were aged 21-61, and the available abstract does not list specific non-serious adverse events. ^[5] This distinction prevents an absence of serious reactions from being read as an absence of all adverse events. ^[5]

For ipamorelin, the phase 2 placebo-controlled bowel-resection study included 114 adults in its safety population. ^[11] It reported treatment-emergent adverse events in 87.5% of the ipamorelin group and 94.8% of the placebo group. ^[11] These percentages describe postoperative patients in that trial only. ^[11]

The available abstract does not specify the adverse-event types. ^[11] It also reports median time to first tolerated meal of 25.3 hours with ipamorelin and 32.6 hours with placebo, with p = 0.15. ^[11] Read that endpoint with its reported statistical result; the numerical difference alone does not establish a reliable advantage.

The CJC-1295 pulsatility abstract and the healthy-volunteer ipamorelin modelling abstract contain no safety statement in the supplied evidence. ^[6][10] Neither the reported events nor a batch certificate establishes the adverse-event profile of the combination. ^[5][11][3]

CJC-1295 and Ipamorelin are both listed in Schedule 4 of the Poisons Standard (prescription only), using the June 2026 instrument checked on 29 September 2026. ^[12] Both are also listed in Appendix D clause 5, which makes possession without authority an offence. ^[12]

Australian scheduling and sport classification are separate checks: Schedule 4 and Appendix D concern the Australian legal classification, while WADA names both compounds under its prohibited-list class. ^[12][13] The Australian peptide legal-status guide explains the scheduling framework.

For laboratory handling of CJC-1295 + Ipamorelin, use four checks: confirm the material, select a compatible solvent, record the concentration, and choose storage for that solvent and peptide preparation. Our house guidance describes these tasks for lyophilised peptides, but provides no blend-specific stability study. ^[15][16] Start with the vial details and requested certificate, because the listed 10mg strength does not specify each component's mass. ^[4][3]

Reconstitution dissolves lyophilised material in a sterile solvent to a known concentration. ^[15] The laboratory reconstitution guide covers the concentration calculation, warming the sealed container before opening, cleaning stoppers, adding solvent down the glass wall, and gentle swirling. ^[15]

As an arithmetic example, 10mg divided by 2 mL gives 5 mg/mL of total labelled material. ^[15] That calculation does not identify the concentration of either component when their individual masses are unspecified. ^[4] HPLC purity is also distinct from net peptide content, which excludes counter-ions and water. ^[15] Establish the mass basis before recording a working concentration.

For storage, the house guide recommends keeping sealed lyophilised peptides dry, dark and at -20°C or colder for long-term storage, with 2 to 8°C for short-term keeping. ^[16] It recommends 2 to 8°C for reconstituted working solutions and labelling the compound, batch, solvent, concentration and opening date. ^[16]

Freezing guidance depends on the solvent. ^[16] The house peptide storage guide keeps BAC Water solutions refrigerated and reserves frozen aliquots for suitable preparations in plain sterile water or buffer. ^[16] That distinction draws partly on antibody research; no stability experiment on this blend was found. ^[16] General handling guidance cannot supply a verified expiry date for the CJC-1295 + Ipamorelin solution. ^[15][16]

Peptides Collective tests every batch before sale through an independent analytical lab, with purity by HPLC and identity by mass spectrometry. ^[3] You can request the certificate using the compound name, strength and batch number. ^[3] Our testing information explains the process; the certificate of analysis information is the related destination for batch-document checks. ^[3]

For this vial, ask for confirmation of the CJC-1295 form and component weights as well as the report. The catalogue supplies a combined 10mg strength but does not resolve those details. ^[4] Read the certificate for the batch you intend to order.

You get tracked dispatch from Perth, Western Australia, twice daily Monday to Friday and once on Saturday. ^[14] Orders ship after payment clears. ^[14] Every order is packed with thermal insulation and plain outer packaging. ^[14]

WA courier costs A$15 and is free on WA orders over A$150; outside WA, delivery is A$24 flat, tracked and requires a signature. ^[14] Check the Australian shipping details against your destination. Twice-daily dispatch describes when parcels leave; arrival depends on the courier. ^[14]

Choose the Peptides Collective CJC-1295 + Ipamorelin 10mg vial for a vial batch tested by an independent lab, a certificate on request and fast tracked dispatch from Perth. ^[4][3][14] Dispatch is twice daily Monday to Friday and once on Saturday, with WA courier free on WA orders over A$150. ^[14] Request the batch report and confirm the component weights and CJC-1295 form before matching the vial to a research method.